deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04251169

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression (TATEN)

Targeting Non-Luminal Disease by PAM50 With Pembrolizumab + Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced/Metastatic Breast Cancer, Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

Sponsor: Merck Sharp & Dohme LLC

Conditions Metastatic Breast Cancer
Interventions Paclitaxel Pembrolizumab
Updated 13 times since 2020 Last updated: Jun 2, 2025 Started: Jul 21, 2020 Primary completion: Apr 10, 2024 Completion: Apr 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The enrollment was stopped prematurely due to the lack of funding

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Metastatic Breast Cancer trials with similar outcome

Browse all Metastatic Breast Cancer trials

A PHASE2 clinical study on Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 13 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~May 2024 · 15 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Jun 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. Feb 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jun 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  4. Sep 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jun 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

  8. Feb 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • SOLTI Breast Cancer Research Group
Data source: SOLTI Breast Cancer Research Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations